cmor logo

Clinical and Molecular Oncology in ColoRectal Cancer

Akershus University Hospital

The CMOR group aims to improve disease outcome for colorectal cancer patients by developing existing and new therapeutic strategies. Tumor hypoxia (deficiency in tissue oxygenation) is recognized as a main mechanism of tumor resistance to cytotoxic therapies, including radiotherapy, and is a major driving force behind metastatic and, incurable disease. Through both experimental laboratory models and clinical studies the group investigates the role of tumor hypoxia in therapy resistance and metastatic progression by employing multiparametric approaches, combining molecular and functional information in order both to portray tumor heterogeneity and facilitate patient treatment stratification. Currently, the group has a particular focus on developing novel predictive and prognostic biomarkers of treatment efficacy and toxicity based on circulating factors and by using state-of-the-art functional imaging (magnetic resonance imaging).


Anne Hansen Ree, Professor, MD, PhD

Position: Group leader, Professor of Oncology, University of Oslo; Consultant Oncologist, Akershus University Hospital

Research interests:Translational treatment studies of targeted therapeutics and radiotherapy in advanced colorectal cancer with correlative biomarker investigations of treatment efficacy and toxicity using molecular, metabolic, and imaging approaches. Mechanistic studies on the role of tumour hypoxia in clinical and experimental colorectal carcinoma models.
Kathrine Røe Redalen, PhD

Position: Senior Scientist

Research interests: Tumor hypoxia and its relevance to disease progression, therapy resistance and metastasis. Functional imaging (MRI, PET) methodologies for detection of hypoxia-mediated cancer aggressiveness, and for evaluation and prediction of therapy response. Circulating biomarkers for prediction of therapy failure and metastatic propensity. Targeted cancer therapies. Molecular radiobiology (kinase activity, exosomes, miRNAs).
Hanne Hamre, MD, PhD

Position: Consultant medical and radiation oncologist, Akershus University Hospital

Research interest: Clinical development of new anti-cancer drugs. Clinical phase II and III trials in medical oncology. Long term side effects after oncological treatment.
Hanna Abrahamsson, MD

Position: PhD Student

PhD Project: Circulating biomarkers of treatment efficacy and tolerability (toxicity) in rectal cancer. Working on material from the LARC-RRP and OxyTarget studies. Co-responsible (together with Sebastian) for inclusion of patients in the OxyTarget study.
Simer Jit Bains, MD PhD

Position: Postdoc

Research interests: Translational research in colorectal cancer and immuno-oncology. To find biomarkers to predict efficiency of immunotherapy in colorectal cancer. Epidemiology with retrospective observational cohort studies in colorectal cancer.
Kine Bakke, PhD

Position: Post Doc

PhD Project: Functional MR imaging for prediction of therapeutic outcome and evaluation of treatment response in rectal cancer. Functional MR imaging for identification of novel, non-invasive biomarkers of tumour hypoxia. Application of MR image analysis tools, biostatistical analysis and multi-parametric prediction models.
Tonje Bjørnetrø, PhD

Position: Post-Doc

PhD Project: Exosomes – biomarkers of hypoxia-induced rectal cancer aggressiveness? Are exosomes carriers of biological information of hypoxia-induced cancer aggressiveness? Are exosomes actors in the metastatic process? Can exosomes become new biomarkers in colorectal cancer?
Paula Bousquet, PhD

Position: Postdoc

Research interests: Mitochondrial function and metabolic alterations associated with tumor hypoxia. Description of mitochondrial DNA dynamics (damage/repair and mutation) in colorectal cancer cell lines and serum samples from study patients. mtDNA modifications as potential circulating biomarker of tumor hypoxia. mtDNA sequencing.
Anniken Jørlo Fuglestad, MD

Position: PhD Student

Research interests: 1. Prognostic role of C-Reactive Protein (CRP) and Glasgow Prognostic Score (GPS) in colorectal cancer; 2. Use of circulating mtDNA and CRP/GPS for patient stratification in colorectal cancer.
Christin Johansen, RN

Position: Study Nurse

Research interest: Patient accrual and care in various translational and clinical trials in colorectal cancer, such as the Metimmox study, MetAction and CapStudien.
Erta Kalanxhi, PhD

Position: Postdoc

Research interests: To understand the mechanisms of action and toxicity of molecularly targeted cancer therapeutics and find novel biomarkers of treatment efficacy and toxicity by combining genomic and proteomic clinical data, which provides invaluable 'real-life' information, and basic scientific research.
Sebastian Meltzer, MD, PhD

Position: Post-Doc

PhD Project: Circulating biomarkers of tumor hypoxia in rectal cancer: 1. Inclusion of patients in the ongoing OxyTarget study, to look at functional MRI as a tool for revealing tumor hypoxia; 2. Data-mining, to look at already existing data from the completed LARC-RRP study, with 5 years of follow-up of more than 100 patients; 3. Laboratory -experiments, to look at colorectal cancer cell lines in order to verify findings from the clinical studies.
Linn Reichborn, MD

Position: PhD Student
Thale Dawn Patrick-Brown, MSc, MIET

Position: Research Coordinator

Research Interests: Epidemiology; anatomy and physiology; protein expression in epithelial tissue; coding and programming of websites (hello world!).
Former Members




Bjørnetrø T, Steffensen LA, Vestad B, Brusletto BS, Olstad OK, Trøseid AM, Aass HCD, Haug KBF, Llorente A, Bøe SO, Lång A, Samiappan R, Redalen KR, Øvstebø R, Ree AH. Uptake of circulating extracellular vesicles from rectal cancer patients and differential responses by human monocyte cultures. (2021). FEBS Open Bio. Jan 29. doi: 10.1002/2211-5463.13098. Epub ahead of print. PMID: 33512765


Bakke KM, Meltzer S, Grøvik E, Negård A, Holmedal SH, Gjesdal KI, Bjørnerud A, Ree AH, Redalen KR. Sex Differences and Tumor Blood Flow from Dynamic Susceptibility Contrast MRI Are Associated with Treatment Response after Chemoradiation and Long-term Survival in Rectal Cancer. (2020). Radiology. Nov;297(2):352-360. doi: 10.1148/radiol.2020200287. Epub 2020 Sep 1. PMID: 32870132

Hannevik TL, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. (2020). Thromb Res. Dec;196:238-244. doi: 10.1016/j.thromres.2020.08.042. Epub 2020 Aug 28. PMID: 32919178

Kalanxhi E, Meltzer S, Ree AH. Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. (2020). Cancers (Basel). Aug 6;12(8):2193. doi: 10.3390/cancers12082193. PMID: 32781554

Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.  (2020).  J Nucl Med. Oct;61(10):1468-1475. doi: 10.2967/jnumed.119.237230. Epub 2020 Apr 3. PMID: 32245896

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K. Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. (2020). Acta Oncol. Jul;59(7):733-740. doi: 10.1080/0284186X.2020.1742377. Epub 2020 Mar 25. PMID: 32208873

Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K. Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. (2020). Cancer Biol Ther. May 3;21(5):432-440. doi: 10.1080/15384047.2020.1721252. Epub 2020 Feb 26. PMID: 3209857

Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Šaltytė Benth J, Johansen JS, Larsen FO, Johansen JS, Ree AH. Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up. Int J Cancer. 2020 Apr 1;146(7):2019-2026. doi: 10.1002/ijc.32847. Epub 2020 Jan 7. PMID: 31872440

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH. Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. Cancer Immunol Immunother. 2020 Mar;69(3):355-364. doi: 10.1007/s00262-019-02458-x. Epub 2019 Dec 31. PMID: 31893287

Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K. Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biol Ther. 2020 May 3;21(5):432-440. doi: 10.1080/15384047.2020.1721252. Epub 2020 Feb 26. PMID: 32098573

Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma. J Nucl Med. 2020 Apr 3:jnumed.119.237230. doi: 10.2967/jnumed.119.237230. Online ahead of print. PMID: 32245896

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Corrigendum to “Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer” [Transl Oncol 12 (8) (2019) 1038-1044]. Transl Oncol. 2020 Jan;13(1):122-124. doi: 10.1016/j.tranon.2019.09.005. PMID: 31843135

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K. Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. Acta Oncol. 2020 Mar 25:1-8. doi: 10.1080/0284186X.2020.1742377. Online ahead of print. PMID: 32208873


Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH. High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer. BMC Cancer. 2019 May 23;19(1):488. doi:10.1186/s12885-019-5724-z. PubMed PMID: 31122213

Bakke KM, Grøvik E, Meltzer S, Negård A, Holmedal SH, Mikalsen LTG, Lyckander LG, Ree AH, Gjesdal KI, Redalen KR, Bjørnerud A. Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrast-based MRI in rectal cancer. J Magn Reson Imaging. 2019 Oct;50(4):1114-1124. doi: 10.1002/jmri.26740. Epub 2019 Apr 4. PubMed PMID: 30945379

Bjørnetrø T, Redalen KR, Meltzer S, Thusyanthan NS, Samiappan R, Jegerschöld C, Handeland KR, Ree AH. An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J Extracell Vesicles. 2019 Jan 29;8(1):1567219. doi:
10.1080/20013078.2019.1567219. eCollection 2019. PubMed PMID: 30728923

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Transl Oncol. 2019 Jan;12(1):76-83. doi:10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29. PubMed PMID: 30273860

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13. PubMed PMID: 31096111

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors? Clin Transl Radiat Oncol. 2019 Dec 2;21:5-10. doi: 10.1016/j.ctro.2019.11.006. eCollection 2020 Mar. PMID: 31872084

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Transl Oncol. 2019 Aug;12(8):1038-1044. doi: 10.1016/j.tranon.2019.04.014. Epub 2019 May 27. PubMed PMID: 31146167

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM. Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer Immunol Res. 2019 May;7(5):701-706. doi: 10.1158/2326-6066.CIR-18-0777. Epub 2019 Feb 25. PubMed PMID: 30804006


Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL. Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer. Clin Chim Acta. 2018 Dec;487:107-111. doi: 10.1016/j.cca.2018.09.029. Epub 2018 Sep 18. PubMed PMID: 30240586

Gopinathan U, Redalen KR, Trøseid AM, Kierulf P, Brandtzaeg P, Ree AH, Berg JP, Øvstebø R. Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis. PLoS One. 2018 Jan 19;13(1):e0181912. doi: 10.1371/journal.pone.0181912. eCollection 2018. PubMed PMID: 29357362

Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T. Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. Eur Heart J Cardiovasc Imaging. 2018 May 1;19(5):544-552. doi: 10.1093/ehjci/jex159. PubMed PMID: 29106497

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26. PubMed PMID: 29695770

2017 and Earlier

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29. PubMed PMID: 29100312

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017. PubMed PMID: 28761742

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR. Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17. PubMed PMID: 28464745.

Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI. Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K(trans) and ΔR2* peak are significantly associated with lymph node metastasis. J Magn Reson Imaging. 2017 Jul;46(1):194-206. doi:10.1002/jmri.25566. Epub 2016 Dec 21. PubMed PMID: 28001320.

Ree AH. Immune-modulating cancer therapy – back to the future. Tidsskr Nor Laegeforen. 2016 Oct 25;136(19):1605. eCollection 2016 Oct. English, Norwegian. PubMed PMID: 27790877.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Br J Cancer. 2016 Oct 11;115(8):929-39. doi: 10.1038/bjc.2016.278. Epub 2016 Sep 6. PubMed PMID: 27599042

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer Res Treat. 2017 Apr;49(2):374-386. doi:10.4143/crt.2016.080. Epub 2016 Jul 28. PubMed PMID: 27488871

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH. Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening. BMC Cancer. 2016 Jul 26;16:536. doi:10.1186/s12885-016-2601-x. PubMed PMID: 27461255

Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer. 2016 Jul 26;16:531. doi: 10.1186/s12885-016-2600-y. PubMed PMID:27461218

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995. PubMed PMID: 27145458

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer – Targeting the tumor for radiation sensitivity? Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8. PubMed PMID: 26968754.

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. Epub 2016 Feb 21. PubMed PMID: 26903532

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K. Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi:10.1016/j.clon.2016.01.014. Epub 2016 Feb 14. PubMed PMID: 26888115.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T. High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17. PubMed PMID: 26705680.

Hektoen HH, Ree AH, Redalen KR, Flatmark K. Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells. J Enzyme Inhib Med Chem. 2016 Oct;31(5):779-86. doi: 10.3109/14756366.2015.1069286. Epub 2015 Aug 5. PubMed PMID: 26244271.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH. Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer. BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6. PubMed PMID: 26205955

Ree AH, Redalen KR. Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol. 2015 Jul;88(1051):20150009. doi: 10.1259/bjr.20150009. Epub 2015 May 20. Review. PubMed PMID: 25989697

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer. Br J Radiol. 2015 Jul;88(1051):20150097. doi: 10.1259/bjr.20150097. Epub 2015 Apr 22. PubMed PMID: 25899892

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR. Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies. Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12. PubMed PMID: 25624177.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E. Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks. Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Review. PubMed PMID: 25501337

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G,
Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review. PubMed PMID: 25347767.

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K. Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy. PLoS One. 2014 Feb 25;9(2):e89750. doi: 10.1371/journal.pone.0089750. eCollection 2014. PubMed PMID: 24587009

Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T. [Cardioprotective treatment during adjuvant cancer therapy]. Tidsskr Nor Laegeforen. 2013 Sep 17;133(17):1832-6. doi: 10.4045/tidsskr.12.1514. Review. Norwegian. PubMed PMID: 24042297.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi:10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10. PubMed PMID: 24035332.

Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLoS One. 2013 Aug 30;8(8):e72692. doi: 10.1371/journal.pone.0072692. eCollection 2013. PubMed PMID: 24023633

Ree AH, Hollywood D. Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience. Radiother Oncol. 2013 Jul;108(1):3-16. doi: 10.1016/j.radonc.2013.06.007. Epub 2013 Jul 3. Review. PubMed PMID: 23830196.

Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH. Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. PLoS One. 2013 May 10;8(5):e63723. doi: 10.1371/journal.pone.0063723. Print 2013. PubMed PMID: 23675504

Hole KH, Larsen SG, Grøholt KK, Giercksky KE, Ree AH. Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer. Radiother Oncol. 2013 May;107(2):178-83. doi: 10.1016/j.radonc.2013.03.017. Epub 2013 Apr 17. PubMed PMID: 23602370.

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K. Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PLoS One. 2012;7(11):e50806. doi: 10.1371/journal.pone.0050806. Epub 2012 Nov 30. PubMed PMID: 23226389

Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T. Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology. 2012;123(4):240-7. doi: 10.1159/000343622. Epub 2012 Nov 30. PubMed PMID: 23207160.

Ree AH. Individualised treatment of metastatic cancer. Tidsskr Nor Laegeforen. 2012 Nov 12;132(21):2358-9. doi: 10.4045/tidsskr.12.1130. English, Norwegian. PubMed PMID: 23160572.

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol. 2012 Sep 27;7:165. doi: 10.1186/1748-717X-7-165. PubMed PMID: 23017053

Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR. Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiat Oncol. 2012 May 23;7:75. doi: 10.1186/1748-717X-7-75. PubMed PMID: 22621752

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer. 2011 Oct 20;11:455. doi: 10.1186/1471-2407-11-455. PubMed PMID: 22014070

Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH. Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis. 2011 Dec;14(4):481-9. doi:10.1007/s10456-011-9231-3. Epub 2011 Aug 11. PubMed PMID: 21833622

Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol. 2011 Jun 8;6:65. doi:10.1186/1748-717X-6-65. PubMed PMID: 21651782

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol. 2011 Apr 8;6:33. doi: 10.1186/1748-717X-6-33. PubMed PMID: 21473790

Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. Neoplasia.
2010 Oct;12(10):818-25. PubMed PMID: 20927320

Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E. Preclinical dynamic 18F-FDG PET – tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol. 2010 Oct;49(7):914-21. doi: 10.3109/0284186X.2010.498831. PubMed PMID: 20831478.

Flatmark K, Ree AH. Radiosensitizing drugs: lessons to be learned from the oxaliplatin story. J Clin Oncol. 2010 Oct 10;28(29):e577-8; author reply e581-3. doi: 10.1200/JCO.2010.30.0921. Epub 2010 Aug 23. PubMed PMID: 20733124.

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH. Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):555-62. doi:
10.1016/j.ijrobp.2010.04.036. Epub 2010 Aug 2. PubMed PMID: 20675069.

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010 May;11(5):459-64. doi:
10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6. PubMed PMID: 20378407.

Bratland A, Vetrhus T, Grøholt KK, Ree AH. Preoperative radiotherapy in rectal signet-ring cell carcinoma – magnetic resonance imaging and treatment outcome: Report of six cases. Acta Oncol. 2010;49(1):42-9. doi: 10.3109/02841860903081897. PubMed PMID: 20100143.

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E. MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiother Oncol. 2009 Nov;93(2):279-84. doi: 10.1016/j.radonc.2009.08.046. Epub 2009 Oct 1. PubMed PMID: 19800704.

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol. 2009 Dec;3(5-6):469-82. doi:10.1016/j.molonc.2009.07.003. Epub 2009 Aug 4. PubMed PMID: 19713161

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068. PubMed PMID: 19427556.

Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH. Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. Clin Exp Metastasis. 2009;26(5):485-96. doi: 10.1007/s10585-009-9248-9. Epub 2009 Mar 18. PubMed PMID: 19294521.

Ree AH, Folkvord S, Flatmark K. HDAC2 deficiency and histone acetylation. Nat Genet. 2008 Jul;40(7):812-3; author reply 813. doi: 10.1038/ng0708-812. PubMed PMID: 18583969.

Ree AH. Highly proliferative neuroendocrine carcinoma – influence of radiotherapy fractionation on tumor response. Radiat Oncol. 2008 May 19;3:13. doi: 10.1186/1748-717X-3-13. PubMed PMID: 18489745

Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF. Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy. Mol Cancer. 2008 Apr 25;7:33. doi: 10.1186/1476-4598-7-33. PubMed PMID: 18439252

Ree AH, Bratland A, Dueland S. [Molecular targeted therapy in colorectal cancer]. Tidsskr Nor Laegeforen. 2008 Jan 17;128(2):190-3. Review. Norwegian. PubMed PMID: 18202731.

Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol. 2008 Mar;86(3):428-34. Epub 2007 Nov 19. PubMed PMID: 18006097.

Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM. Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation. Eur J Gynaecol Oncol. 2007;28(5):356-63. PubMed PMID: 17966213.

Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM. Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1. BMC Cardiovasc Disord. 2006 Oct 9;6:40. PubMed PMID: 17029634

Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol. 2006 Aug 3;1:25. PubMed PMID: 16887021

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y. DNA damage responses in cell cycle G2 phase and mitosis–tracking and targeting. Anticancer Res. 2006 May-Jun;26(3A):1909-16. PubMed PMID: 16827124.

Ree AH. A complex case of rectal neuroendocrine carcinoma with terminal delirium. Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):408-13; quiz 414. PubMed PMID: 16819503.

Porojnicu AC, Robsahm TE, Ree AH, Moan J. Season of diagnosis is a prognostic factor in Hodgkin’s lymphoma: a possible role of sun-induced vitamin D. Br J Cancer. 2005 Sep 5;93(5):571-4. PubMed PMID: 16136030

Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol Cancer Ther. 2005 Aug;4(8):1231-8. PubMed PMID: 16093439.

Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T. Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype. Int J Cancer. 2005 Jul 20;115(6):935-42. PubMed PMID: 15723354.

DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089. J Steroid Biochem Mol Biol. 2004 Dec;92(5):365-74. Epub 2004 Dec 21. PubMed PMID: 15698541.

Ree AH. [Cell cycle-targeted therapy]. Tidsskr Nor Laegeforen. 2004 Oct 7;124(19):2479-82. Norwegian. PubMed PMID: 15477884.

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y. Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization? Radiother Oncol. 2004 Sep;72(3):305-10. PubMed PMID: 15450729.

Johansson CC, Yndestad A, Enserink JM, Ree AH, Aukrust P, Taskén K. The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3′,5′-monophosphate pathway in various cell types. Endocrinology. 2004 Nov;145(11):5177-84. Epub 2004 Jul 29. PubMed PMID: 15284208.

Ree AH, Bratland A, Solberg Landsverk K, Fodstad O. Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner. Anticancer Res. 2004 Mar-Apr;24(2B):555-62. PubMed PMID: 15160994.

Ree AH, Bratland A, Nome RV, Stokke T, Fodstad Ø. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene. 2003 Dec 4;22(55):8952-5. PubMed PMID: 14654792.

Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clin Exp Metastasis. 2003;20(6):541-7. PubMed PMID: 14598888.

Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM. Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer Res. 2002 Jul-Aug;22(4):1949-57. PubMed PMID: 12174869.

Ree AH, Engebraaten O, Hovig E, Fodstad Ø. Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells. Int J Cancer. 2002 Jan 1;97(1):28-33. PubMed PMID: 11774240.

Bjørnland K, Bratland A, Rugnes E, Pettersen S, Johansen HT, Aasen AO, Fodstad Ø, Ree AH, Maelandsmo GM. Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells. J Pediatr Surg. 2001 Jul;36(7):1040-4. PubMed PMID: 11431772.

Bratland A, Risberg K, Maelandsmo GM, Gützkow KB, Olsen OE, Moghaddam A, Wang MY, Hansen CM, Blomhoff HK, Berg JP, Fodstad O, Ree AH. Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. Cancer Res. 2000 Oct 1;60(19):5578-83. PubMed PMID: 11034106.

Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res. 2000 May;6(5):1778-83. PubMed PMID: 10815897.

Grønning LM, Wang JE, Ree AH, Haugen TB, Taskén K, Taskén KA. Regulation of tissue inhibitor of metalloproteinases-1 in rat Sertoli cells: induction by germ cell residual bodies, interleukin-1alpha, and second messengers. Biol Reprod. 2000 Apr;62(4):1040-6. PubMed PMID: 10727275.

Røsok O, Pedeutour F, Ree AH, Aasheim HC. Identification and characterization of TESK2, a novel member of the LIMK/TESK family of protein kinases, predominantly expressed in testis. Genomics. 1999 Oct 1;61(1):44-54. PubMed PMID: 10512679.

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O. Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res. 1999 Sep 15;59(18):4675-80. PubMed PMID: 10493524.

Ståhl S, Odeberg J, Larsson M, Røsok O, Ree AH, Lundeberg J. Solid-phase differential display and bacterial expression systems in selection and functional analysis of cDNAs. Methods Enzymol. 1999;303:495-511. PubMed PMID: 10349662.

Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA. Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid. Biol Reprod. 1999 May;60(5):1257-62. PubMed PMID: 10208993.

Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997 Sep;3(9):1623-8. PubMed PMID: 9815852.

Bjørnland K, Lehne G, Johansen HT, Fodstad O, Rugstad HE, Aasen AO, Ree AH. Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells. Oncol Res. 1998;10(5):255-62. PubMed PMID: 9802060.

Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O. Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis. 1998 Apr;16(3):205-15. PubMed PMID: 9568638.

Ree AH, Maelandsmo GM, Fodstad O. Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: comparison with regulatory mechanisms of pS2 expression. Clin Exp Metastasis. 1996 Sep;14(4):381-8. PubMed PMID: 8878412.

Berg JP, Ree AH, Sandvik JA, Taskén K, Landmark BF, Torjesen PA, Haug E. 1,25-dihydroxyvitamin D3 alters the effect of cAMP in thyroid cells by increasing the regulatory subunit type II beta of the cAMP-dependent protein kinase. J Biol Chem. 1994 Dec 23;269(51):32233-8. PubMed PMID: 7798223.

Berg JP, Sandvik JA, Ree AH, Sørnes G, Bjøro T, Torjesen PA, Gordeladze JO, Haug E. 1,25-Dihydroxyvitamin D3 attenuates adenylyl cyclase activity in rat thyroid cells: reduction of thyrotropin receptor number and increase in guanine nucleotide-binding protein Gi-2 alpha. Endocrinology. 1994 Aug;135(2):595-602. PubMed PMID: 8033808.

Ree AH, Taskén K, Hansson V. Regulation of glucocorticoid receptor (GR) mRNA and protein levels by phorbol ester in MCF-7 cells. Mechanism of GR mRNA induction and decay. J Steroid Biochem Mol Biol. 1994 Jan;48(1):23-9. PubMed PMID: 8136303.

Ree AH, Knutsen HK, Landmark BF, Eskild W, Hansson V. Down-regulation of messenger ribonucleic acid (mRNA) for the estrogen receptor (ER) by phorbol ester requires ongoing RNA synthesis but not protein synthesis. Is hormonal control of ER mRNA degradation mediated by an RNA molecule? Endocrinology. 1992 Oct;131(4):1810-4. PubMed PMID: 1382961.

Kise NJ, Bergsmark JK, Endreseth BH, Reinertsen KV, Ugelstad TP, Ree AH. [Living and dying alone. An epidemiological study of deaths outside institutions in Oslo in 1989]. Tidsskr Nor Laegeforen. 1992 Feb 20;112(5):616-9. Norwegian. PubMed PMID: 1557724.

Ree AH, Landmark BF, Walaas SI, Lahooti H, Eikvar L, Eskild W, Hansson V. Down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors by phorbol ester and calcium in MCF-7 cells. Endocrinology. 1991 Jul;129(1):339-44. PubMed PMID: 2055193.

Eskild W, Ree AH, Levy FO, Jahnsen T, Hansson V. Cellular localization of mRNAs for retinoic acid receptor-alpha, cellular retinol-binding protein, and cellular retinoic acid-binding protein in rat testis: evidence for germ cell-specific mRNAs. Biol Reprod. 1991 Jan;44(1):53-61. PubMed PMID: 1849753.

Ree AH, Frøysa A, Eskild W, Jahnsen T, Hansson V. Biphasic regulation of the messenger ribonucleic acid coding for the estrogen receptor by cyclic adenosine 3′:5′-monophosphate in tumor Leydig cells. Cancer Res. 1990 Mar 1;50(5):1528-31. PubMed PMID: 2154326.

Ree AH, Landmark BF, Eskild W, Levy FO, Lahooti H, Jahnsen T, Aakvaag A, Hansson V. Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels. Endocrinology. 1989 May;124(5):2577-83. PubMed PMID: 2651098.

Levy FO, Ree AH, Eikvar L, Govindan MV, Jahnsen T, Hansson V. Glucocorticoid receptors and glucocorticoid effects in rat Sertoli cells. Endocrinology. 1989 Jan;124(1):430-6. PubMed PMID: 2909375.

Ree AH, Jensen LB. Spinal leptomeningeal carcinosis visualized by amipaque myelography. Neuroradiology. 1979 May 15;17(5):283-4. PubMed PMID: 481747.


Leave a Reply